Longevity & AgingOral GLP-1 Pill Orforglipron Cuts Blood Sugar and Weight in Early Diabetes
The ACHIEVE-1 trial tested orforglipron, a first-of-its-kind oral small-molecule GLP-1 receptor agonist, in 559 adults with early type 2 diabetes managed by diet and exercise alone. Over 40 weeks, all three doses (3 mg, 12 mg, 36 mg) significantly reduced HbA1c versus placebo, bringing average levels to 6.5–6.7%. Body weight also dropped meaningfully, with the highest dose achieving a 7.6% reduction. Gastrointestinal side effects were mild to moderate, mainly during dose escalation. No severe hypoglycemia was recorded. These results position orforglipron as a potentially accessible, injection-free alternative to injectable GLP-1 therapies for metabolic disease management.
